3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
1
Recurrence
1
Neoplasms
1
Neoplasm Metastasis
1
Bone Neoplasms
1
Bone Metastasis From Solid Tumors
1
Interventions
Cyclophosphamide
3
pembrolizumab
2
Radiotherapy
2
Radiation
2
Gemcitabine
2
Etoposide
2
Doxorubicin
2
Cryotherapy
2
Cryosurgery
2
tocilizumab
1
selinexor
1
robatumumab
1
poly ICLC
1
olaparib
1
montanide ISA 51
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
flt3 ligand protein
1
eltrombopag
1
cc-486
1
Vincristine
1
Trabectedin
1
Temozolomide
1
Radiotherapy, Intensity-Modulated
1
Leukapheresis
1
Irinotecan
1
Interleukin-2
1
Injections
1
Imiquimod
1
Ifosfamide
1
Denosumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Bone Neoplasms
×
Denosumab
×
Clear all
NCT04798326
2021-03-15
MW032
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
Completed
120 enrolled